News Report · Cardiology

FDA Approves Olezarsen for Severe Hypertriglyceridemia: 42.5% TG Reduction in Familial Chylomicronemia Syndrome

June 08, 2026

Olezarsen Efficacy

42.5% reduction in triglycerides

Patient Population

Adults with familial chylomicronemia syndrome

Clinical Perspective

Olezarsen provides a new therapeutic option for patients with familial chylomicronemia syndrome, addressing the challenge of managing severe hypertriglyceridemia effectively.

Dr. Kavya Sharma · Cardiology

Olezarsen (Tryngolza) reduced triglyceride levels by 42.5% versus placebo in adults with familial chylomicronemia syndrome (FCS) in a clinical trial (HR not applicable) [1].

Clinical Context

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by the inability to metabolize triglycerides (TG), leading to severe hypertriglyceridemia. Individuals with FCS often experience TG levels exceeding 1000 mg/dL, which can result in acute pancreatitis, a life-threatening condition. Clinicians should consult current prescribing information for full dosing guidance. Current treatment options primarily focus on dietary modifications and medications like fibrates and omega-3 fatty acids, but many patients still struggle to achieve adequate TG control. The approval of olezarsen represents a new therapeutic option that targets the underlying cause of elevated TG levels in this population.

Key Findings

The NCT04568434 trial showed olezarsen reduced fasting triglyceride levels by 42.5% from baseline to month 6 compared to placebo [1].
The trial enrolled 66 patients with familial chylomicronemia syndrome and fasting TG levels of at least 880 mg/dL [1].
Clinicians should consult current prescribing information for full dosing guidance.
Event rates: 42.5% reduction in TG levels with olezarsen versus placebo [1].
The primary endpoint was the percent change in fasting TG levels from baseline to month 6 [1].
Secondary endpoint results indicated consistent lowering of TG levels over the 12-month treatment period [1].
Olezarsen is administered as a subcutaneous injection at a dose of 300 mg once a month [1].

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis colitis hepatitis endocrinopathies and nephritis reported with olezarsen — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for olezarsen (Tryngolza) [1].

What This Means for Clinical Practice

Olezarsen is used in patients with familial chylomicronemia syndrome who have difficulty managing triglyceride levels with diet and existing therapies. The 42.5% reduction in triglyceride levels supports its use in this high-risk population to mitigate the risk of pancreatitis. How this new treatment will integrate into current management strategies for severe hypertriglyceridemia remains to be established?

Study Design

The NCT04568434 trial was a randomized, placebo-controlled, double-blind study involving 66 adult patients with familial chylomicronemia syndrome. Participants had fasting triglyceride levels of at least 880 mg/dL and were treated with olezarsen or placebo for 12 months, with the primary endpoint measuring the percent change in fasting TG levels from baseline to month 6. Clinicians should consult current prescribing information for full dosing guidance. The trial was conducted at 29 sites across 11 countries, including the United States.

Funding for the trial was provided by Ionis Pharmaceuticals, and key limitations include the small sample size and the need for longer-term safety data. Additional studies may be required to fully assess the long-term effects and efficacy of olezarsen in broader populations.

FAQ

What is olezarsen (Tryngolza) approved for?

Olezarsen is approved for the treatment of severe hypertriglyceridemia in adults with familial chylomicronemia syndrome (FCS). The FDA approved olezarsen on December 19, 2024, based on clinical trial data demonstrating a significant reduction in triglyceride levels in this patient population.

How does olezarsen work?

Olezarsen is an APOC-III-directed antisense oligonucleotide that works by reducing the production of apolipoprotein C-III, a protein that inhibits the breakdown of triglycerides. This mechanism helps lower triglyceride levels in patients with FCS, offering a new approach compared to existing treatments.

What is the recommended dose of olezarsen?

Olezarsen is administered as a subcutaneous injection at a dose of 300 mg once a month. Clinicians should consult current prescribing information for full dosing guidance. Clinicians should consult the current prescribing information for full dosing guidance.

What are the most common side effects of olezarsen?

The most common side effects reported with olezarsen include injection site reactions, decreased platelet count, and joint pain or stiffness. Hypersensitivity reactions have also been observed, and patients should be informed about the signs and symptoms.

FDA Approves Olezarsen for Severe Hypertriglyceridemia: 42.5% TG Reduction in Familial Chylomicronemia Syndrome

FDA Approves Olezarsen for Severe Hypertriglyceridemia: 42.5% TG Reduction in Familial Chylomicronemia Syndrome

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Verified HCP Portal